ImmunityBio’s stock experienced an upward movement following the National Comprehensive Cancer Network’s (NCCN) revised clinical guidelines for bladder cancer. The updated recommendations now incorporate Anktiva, in conjunction with Bacillus Calmette-Guérin (BCG), for managing BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) characterized by papillary-only disease. This expansion builds upon prior NCCN guidelines, which already sanctioned its use for NMIBC patients with carcinoma in situ (CIS), with or without papillary disease, both classified under Category 2A.

This innovative immunotherapy is engineered to stimulate both natural killer (NK) cells and T cells, demonstrating sustained therapeutic benefits in various clinical investigations. While the NCCN’s latest recommendation for papillary-only disease extends beyond the current U.S. Food and Drug Administration (FDA) approved indications for Anktiva, it signals a significant shift towards immune-centric treatments. Richard Adcock, ImmunityBio's President and CEO, highlighted that this guideline update affirms the evolving clinical consensus for patient care and underscores the vital role of immune-based interventions. The company is actively collaborating with insurance providers and healthcare organizations to promote awareness and ensure appropriate access to the therapy, in line with its approved labeling. Anktiva, sanctioned by the FDA in April 2024 for combined use with BCG, is already covered by insurance plans serving over 100 million patients across the United States.

ImmunityBio has been proactive in its efforts to broaden Anktiva’s reach, including a recent resubmission to the FDA for an expanded indication in treating BCG-unresponsive NMIBC. This action followed discussions with the FDA in January 2026, which prompted the submission of additional efficacy data in March. Concurrently, the company successfully concluded its NK2022 and NK2023 programs, which assessed the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy, involving 64 participants with no serious adverse events. This achievement validates the company’s capacity to produce up to five billion NK cells from a single apheresis collection. Furthermore, ImmunityBio is advancing its phase 1 QUILT-3.076 trial, which combines M-ceNK cells with Anktiva, showing promising anti-tumor effects across various cancer types. The positive sentiment is echoed by analyst consensus, with the stock maintaining a "Buy" rating and an average price target of $12.57, reflecting strong confidence from firms like BTIG, D. Boral Capital, and Piper Sandler.

The progression of medical science, particularly in immunotherapies like Anktiva, offers profound hope for patients battling severe diseases. These advancements exemplify humanity's relentless pursuit of better health outcomes and the innovative spirit driving scientific discovery. Embracing such breakthroughs not only transforms individual lives but also inspires a collective belief in a future where daunting medical challenges can be overcome through dedication and pioneering research.